
According to Benzinga Pro data, during Q4, Exagen (NASDAQ:XGN) posted sales of $12.69 million. Earnings were up 1.76%, but Exagen still reported an overall loss of $7.05 million. In Q3, Exagen brought in $12.25 million in sales but lost $7.18 million in earnings.